Navigation Links
New Phase 3 Study Results Show REMICADE® is Effective in the Treatment of Pediatric Patients With Moderate to Severe Ulcerative Colitis
Date:5/9/2011

CHICAGO, May 9, 2011 /PRNewswire/ -- Data from a Phase 3 randomized, multicenter, open-label study demonstrated clinical response with REMICADE® (infliximab) in the treatment of pediatric patients with moderately to severely active ulcerative colitis (UC), and showed a safety profile consistent with previous clinical trials conducted in an adult population.  The pediatric UC findings, presented today at Digestive Disease Week, showed REMICADE induced clinical response in 73 percent of patients aged 6-17 years at week 8, the primary endpoint of the trial.  REMICADE received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with moderately to severely active UC in September 2005 and in October 2006, REMICADE received FDA approval for maintaining clinical remission and mucosal healing indications in adults living with UC.

UC is a chronic inflammatory bowel disease (IBD) of the colon.  It is estimated that 1.4 million Americans have IBD with the number evenly split between UC and Crohn's disease.  An estimated 150,000 children under age 17 are living with debilitating symptoms of IBD.(1)  

"The results of this study are consistent with findings from the Active Ulcerative Colitis (ACT) trials, which evaluated REMICADE in the treatment of adults with ulcerative colitis," said Jeffrey Hyams, Head of the Division of Digestive Diseases and Nutrition at Connecticut Children's Medical Center and Professor of Pediatrics at University of Connecticut School of Medicine, and lead study investigator.  "UC can be a devastating disease, particularly for children and adolescents.  It is encouraging to see such promising results in a patient population that is in need of additional treatment options."

In December 2010, Centocor Ortho Biotech Inc. submitted a supplemental Biologics License Application (sBLA) to the FDA requesting the approval of REMICADE (infliximab) for the treatment of modera
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... browsing of chemistry in documents ... solutions and consulting services for life science research, ... and generate Markush structures from documents. ... intellectual property, however generating and understanding Markush structures ...
(Date:9/30/2014)... Genedata, a leading provider ... and related life science research, today announced ... Selector as its host-pathogen data analysis platform ... a European consortium dedicated to improving the ... anti-fungal drug therapies. Genedata Selector supports this ...
(Date:9/30/2014)... OriginOil Inc. (OTC/QB: OOIL), developer of ... clean up large quantities of water, announced today that ... on the launch of the company's CLEAN-FRAC™ industrial grade ... partner STW Resources . , Immediately upon startup, ... (bpd) and achieved a 99.8% reduction in Turbidity on ...
(Date:9/30/2014)... Sept. 30, 2014  KemPharm, Inc., a clinical-stage ... development of proprietary new molecular entity (NME) prodrugs, ... Trademark Office (USPTO) issued U.S. Patent No. 8,816,083 ... Acid, Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid ... Use Thereof." The patent, which extends ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 2FUNGITECT Consortium Adopts Genedata Selector as Data Analysis Platform for Anti-fungal R 3OriginOil, Inc. Report to Shareholders: Blue Gold in West Texas 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2
... Ill. University of Illinois engineers have developed ... that could shrink integrated circuits and expand microelectronics. ... multiple transistors and electronic components together to perform ... boards traditionally are made from pre-fabricated metal wires ...
... ,, NEW YORK , July 15 Senesco Technologies (NYSE Amex: SNT ) announces the following ... What:  LHA Life Sciences & Med Tech Day 2010 Presentation , , ... Eastern , , , ... How:  Live over the Internet -- Simply log on to the web at the ...
... , QUEBEC CITY , July 14 ... TSX: AEZ) (the "Company"), a late-stage drug development ... announced that its partner, Keryx Biopharmaceuticals, Inc. ("Keryx") ... the U.S. Food and Drug Administration ("FDA") for ...
Cached Biology Technology:Small wires make big connections for microelectronics 2Small wires make big connections for microelectronics 3Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 3Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 4
(Date:9/30/2014)... Mass. , Sept. 30, 2014 /PRNewswire/ ... control solutions for the biotech and power ... its new RECONN Bioprocess Manager, an easy-to-use ... solution geared towards bioprocess development laboratories. ... have disparate bioreactor and analyzer systems. Accessing ...
(Date:9/30/2014)... threats in today,s ocean. From overfishing and pollution ... ecosystems are disappearing at unprecedented rates around the ... surrounding the island of Moorea in French Polynesia ... coral guard-crabs. New research from the National Museum ... McKeon and the museum,s predoctoral fellow Jenna Moore ...
(Date:9/30/2014)... who suffer from asthma may think there,s not a ... properly taking medications and avoiding allergic triggers. , ... of Allergy, Asthma and Immunology , the scientific publication ... (ACAAI), asthma sufferers can learn lessons about managing their ... the Annals article improved her asthma once she and ...
Breaking Biology News(10 mins):Spectra Automation Introduces RECONN Bioprocess Manager 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... become more crucial to fundamental global issues, including ... Diego,s Jacobs School of Engineering,s top ranked bioengineering ... of this field. The Siebel Foundation has ... $2 million endowment to fund fellowships for some ...
... Ann Arbor, Mich. University of Michigan scientists ... more precise way for medics and fellow soldiers in ... and a drug that limits morphine,s dangerous side effects. ... particles capable of carrying the drugs into the body. ...
... Service Eastern Forest Environmental Threat Assessment Center (EFETAC) ... Tools (CRAFT), a user-friendly, Web-based support system that ... land management decisions. CRAFT offers a ... risks and tradeoffs associated with different management scenarios. ...
Cached Biology News:Siebel Foundation awards top UC San Diego bioengineering graduate students 2Siebel Foundation awards top UC San Diego bioengineering graduate students 3Siebel Foundation awards top UC San Diego bioengineering graduate students 4Nanoparticle-based battlefield pain treatment moves a step closer 2Forest Service Web-based tool helps manage environmental risk 2
... acid analysis standard is a ... salts; molecular weights range from ... is provided for use with ... the organic acid analysis kit ...
... demonstrated that oxidative stress is involved in ... stress is the condition in which an ... exist leading to the damage of a ... stress is through several antioxidant systems4 that ...
... matrix for the extraction of unwanted ... other macromolecules, Applications: ,Reducing octyl glucoside ... interaction of pure β-adrenergic receptor and ... SDS in 6 M urea/0.05 mM ...
Values of steady state parameters for enzyme activities are determined....
Biology Products: